Everything below concerns peptide backbone. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
=== Protein purification === When purifying protein from a biological extract, streptomycin sulfate is sometimes added as a means of removing nucleic acids and ribonuclear proteins. Since it binds to ribosomes and precipitates out of solution, it serves as a method for removing rRNA, mRNA, and even DNA if the extract is from a prokaryote.
The first report of the discovery of element 105 came from the Joint Institute for Nuclear Research (JINR) in Dubna, Moscow Oblast, Soviet Union, in April 1968. The scientists bombarded 243Am with a beam of 22Ne ions, and reported 9.4 MeV (with a half-life of 0.1–3 seconds) and 9.7 MeV (t1/2 > 0.05 s) alpha activities followed by alpha activities similar to those of either 256103 or 257103. Based on prior theoretical predictions, the two activity lines were assigned to 261105 and 260105, respectively.
in the version dated April 30, 2003 - that their specialist knowledge in radiation protection has been updated and must complete a full-day course with a final examination. Specialist knowledge in radiation protection is required by the Technical Knowledge Guideline according to X-ray Ordinance. - R3 for persons who work with baggage screening equipment, industrial measuring equipment and interfering emitters. Since 2019, the regulatory areas of the previous X-ray and radiation protection ordinances have been merged in the amended Radiation Protection Ordinance. The Radiation Protection Commission (SSK) was founded in 1974 as an advisory body to the Federal Ministry of the Interior. It emerged from Commission IV "Radiation Protection" of the German Atomic Energy Commission, which was founded on January 26, 1956. After the Chernobyl nuclear disaster in 1986, the Federal Ministry for the Environment, Nature Conservation, Nuclear Safety and Consumer Protection was established in the Federal Republic of Germany. The creation of this ministry was primarily a response to the perceived lack of coordination in the political response to the Chernobyl disaster and its aftermath. On December 11, 1986, the German Bundestag passed the Precautionary Radiation Protection Act (StrVG) to protect the population, to monitor radioactivity in the environment, and to minimize human exposure to radiation and radioactive contamination of the environment in the event of radioactive accidents or incidents. The last revision of the X-Ray Ordinance was issued on January 8, 1987.
Sources: en.wikipedia.org
=== Types === 2-keto compounds: clorazepate, diazepam, flurazepam, halazepam, prazepam, and others 3-hydroxy compounds: lorazepam, lormetazepam, oxazepam, temazepam 7-nitro compounds: clonazepam, flunitrazepam, nimetazepam, nitrazepam Triazolo compounds: adinazolam, alprazolam, estazolam, triazolam Imidazo compounds: climazolam, loprazolam, midazolam 1,5-benzodiazepines: clobazam
==== National honors ==== Knight Grand Cross of Rizal (KGCR) – (2017) Awards for Promoting Philippines-China Understanding (APPCU), Hall of Fame – (2023) Integrated Bar of the Philippines Golden Pillar of Law Award – (2025)
== Childhood obesity == Childhood obesity and adolescent obesity have also increased in Brazil. National surveys and international reports have identified Brazil as one of the countries experiencing a rapid rise in obesity among children and adolescents. Public health experts have expressed concern that increasing childhood obesity may contribute to future increases in diabetes, cardiovascular disease, and healthcare expenditures. The World Obesity Federation has highlighted childhood obesity as an emerging public health challenge in Brazil and throughout Latin America.
Sources: en.wikipedia.org
The scientific Latin term octopus was derived from Ancient Greek ὀκτώπους (oktōpous), a compound form of ὀκτώ (oktō, 'eight') and πούς (pous, 'foot'), itself a variant form of ὀκτάπους, a word used for example by Alexander of Tralles (c. 525 – c. 605). The standard pluralised form of octopus in English is octopuses; the Ancient Greek plural ὀκτώποδες, octopodes (), has also been used historically. The alternative plural octopi is usually considered etymologically incorrect, because it wrongly assumes that octopus is a Latin second-declension -us noun or adjective when, in either Greek or Latin, it is a third-declension noun. Historically, the first plural to commonly appear in English language sources, in the early 19th century, is the Latinate form octopi, followed by the English form octopuses in the latter half of the same century. The Hellenic plural is roughly contemporary in usage, although it is also the rarest. A Dictionary of Modern English Usage by H. W. Fowler states that the only acceptable plural in English is octopuses, that octopi is misconceived, and octopodes pedantic; the last is nonetheless used frequently enough to be acknowledged by the descriptivist Merriam-Webster 11th Collegiate Dictionary and Webster's New World College Dictionary. The Oxford English Dictionary lists octopuses, octopi, and octopodes, in that order, reflecting frequency of use, calling octopodes rare and noting that octopi is based on a misunderstanding.
=== Clinical medicine === In clinical medicine, sterile test tubes with air removed, called vacutainers, are used to collect and hold samples of physiological fluids such as blood, urine, pus, and synovial fluid. These tubes are commonly sealed with a rubber stopper and often have a specific additive placed in the tube with the stopper color indicating the additive. For example, a blue-top tube is a 5 ml test tube containing sodium citrate as an anticoagulant, used to collect blood for coagulation and glucose-6-phosphate dehydrogenase testing. Small vials used in medicine may have a snap-top (also called a hinge cap) molded as part of the vial.
==== Hydroxyurea ==== Hydroxyurea is another drug that can sometimes be administered to relieve anemia caused by beta-thalassemia. This is achieved, in part, by reactivating fetal haemoglobin production; however its effectiveness is uncertain.
They finished second behind Manchester United however, losing their slender advantage once they lost their penultimate match. United also eliminated Arsenal in a FA Cup semi-final replay after extra time; Wenger afterwards said: "it was a smashing game, and in the end, the luckiest won." In August 1999, Anelka joined Real Madrid, having threatened to strike if Arsenal did not grant him a move abroad. Wenger used a portion of the proceeds generated through the Anelka sale to fund the build of the Arsenal Training Centre, expressing his desire to establish a "home away from Arsenal". He renewed his forward line by signing Davor Šuker from Real Madrid, and Thierry Henry, who joined after seven "injury-interrupted" months at Juventus for £11.5 million. It was Wenger's intention to partner Anelka with Henry, but the former's departure meant the plan was scrapped. The following seasons were comparatively barren. Arsenal again exited the Champions League at the group stage, but dropped down to the UEFA Cup. Wenger guided his team to the final, where they lost to Galatasaray on penalties. In the league, Arsenal finished 18 points behind Manchester United as runners-up, and though they closed the gap to eight points in 2000–01, they never posed a serious title challenge. The trophy drought continued past 2001, when Michael Owen scored two late goals for Liverpool to beat Arsenal in the FA Cup Final. Wenger rued his team's inability to make possession count, but refused to blame individuals, namely Henry, for missing chances.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.